Missing data casts doubt on Tamiflu spend

A leading clinician has questioned the wisdom of spending millions of dollars stockpiling oseltamivir (Tamiflu) if unreleased trial data puts in question its efficacy against flu complications.

Professor Chris Del Mar, Professor of Public Health at Bond University, says the taxpayer may have been "sold a pup" because lack of access to trial data meant clinicians had no way to verify whether Tamiflu was effective against severe influenza.

Writing in

Latest